ROCKAWAY, NJ , May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June. The conferencing details are as follows: Summer
Record First quarter 2021 net sales of $1.2 million , increased 64% over first quarter 2020 and 30% sequentially Company to host a conference call and webcast today, May 6, 2021 at 4:30 pm ET ROCKAWAY, N.J. , May 06, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.
ROCKAWAY, NJ , May 04, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the U.S. Department of Veterans Affairs is starting an investigator-initiated study of the use of gammaCore Sapphire TM non-invasive vagus nerve
ROCKAWAY, NJ , April 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2021 after the close of the market on Thursday, May 6, 2021 .
ROCKAWAY, NJ , April 26, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS)
ROCKAWAY, NJ , April 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with East Agency to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve
ROCKAWAY, NJ , April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Cluster headache pathophysiology — insights from current and emerging treatments,” by Drs.
First-quarter 2021 revenue expected to be more than $1.1 million Net cash used for the first quarter 2021 of approximately $4.1 million ROCKAWAY, NJ , April 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an
nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of treatment ROCKAWAY, NJ , April 08, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the top-line results from the SAVIOR-1
ROCKAWAY, NJ , April 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Canada for prevention